18:54 , Aug 31, 2018 |  BC Week In Review  |  Company News

Affimed, Genentech in NK cell engager deal

Affimed N.V. (NASDAQ:AFMD) said late Aug. 27 that it partnered with the Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY) to develop and commercialize NK cell engager-based immunotherapeutics to treat cancers. The news sent Affimed shares...
22:16 , Aug 27, 2018 |  BC Extra  |  Company News

Affimed, Genentech in NK cell engager deal

Affimed N.V. (NASDAQ:AFMD) said late Monday that it partnered with the Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY) to develop and commercialize NK cell engager-based immunotherapeutics to treat cancers. The news sent Affimed shares up...
21:47 , Mar 19, 2018 |  BC Extra  |  Company News

Management tracks: J&J, Alder, CVS

Johnson & Johnson (NYSE:JNJ) said EVP and CFO Dominic Caruso will retire in September. He is succeeded by VP of investor relations Joseph Wolk. Alder BioPharmaceuticals Inc. (NASDAQ:ALDR) said President and CEO Randall Schatzman will step...
00:05 , Feb 17, 2018 |  BC Week In Review  |  Financial News

Affimed raises $26.5M in follow-on

Cancer company Affimed N.V. (NASDAQ:AFMD) raised $26.5 million through the sale of 13.2 million shares at $2 in a follow-on underwritten by Jefferies and Wells Fargo. The figures include the sale of a 1.7 million...
20:50 , Feb 16, 2018 |  BC Week In Review  |  Financial News

Affimed raises $26.5M in follow-on

Cancer company Affimed N.V. (NASDAQ:AFMD) raised $26.5 million through the sale of 13.2 million shares at $2 in a follow-on underwritten by Jefferies and Wells Fargo. The figures include the sale of a 1.7 million...
18:44 , Feb 9, 2018 |  BC Week In Review  |  Clinical News

Affimed reports Phase Ib/IIa data of AFM13 for cutaneous lymphoma

Affimed N.V. (NASDAQ:AFMD) reported data from three evaluable patients with relapsed or refractory CD30-positive, cutaneous lymphoma in the first dose cohort of a Phase Ib/IIa trial showing that once-weekly 1.5 mg/kg IV AFM13 led to...
18:44 , Feb 9, 2018 |  BC Week In Review  |  Clinical News

Affimed reports Phase Ib data of AFM13 plus Keytruda for Hodgkin's lymphoma

Affimed N.V. (NASDAQ:AFMD) reported data from nine evaluable patients with relapsed or refractory Hodgkin's lymphoma in a Phase Ib trial showing that 7 mg/kg IV AFM13 plus anti-PD-1 mAb Keytruda pembrolizumab from Merck & Co....
02:10 , Dec 8, 2017 |  BC Innovations  |  Targets & Mechanisms

Epiphenomena at ASH

While it’s no surprise that cell therapy research is dominant in hematology, the emergence of epigenetics as an equally large focus at this year’s ASH meeting is more notable, reinforcing the resurgence of a field...
21:53 , Dec 1, 2017 |  BC Week In Review  |  Company News

AbCheck, Molecular Templates partner to identify oncology antibodies

Affimed N.V. (NASDAQ:AFMD) subsidiary AbCheck s.r.o. (Plzen, Czech Republic) and Molecular Templates Inc. (NASDAQ:MTEM) partnered to discover antibodies to treat cancer. AbCheck will use its AbSieve discovery technology to identify antibodies against targets selected by...
22:03 , Sep 18, 2017 |  BC Extra  |  Company News

Management tracks: Kamada, Vertex, Addex, Achillion

Orphan disease company Kamada Ltd. (Tel Aviv:KMDA; NASDAQ:KMDA) said Deputy CEO and CFO Gil Efron will leave at the end of the year. Chaime Orlev will become CFO, effective Jan. 1, 2018. Orlev was CFO...